Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Cole, D. P. Articles by Frank, E. Search for Related Content PubMed Citation Articles by Cole, D. P. Articles by Frank, E. Neuroendocrinology Bipolar Disorder Depression Antidepressants Lithium

Slower Treatment Response in Bipolar Depression Predicted by Lower Pretreatment Thyroid Function

OBJECTIVE: Because treatment of the depressed phase of bipolar disorder is a clinical challenge and hypothyroidism is known to be associated with depression, the authors examined the relationship between pretreatment thyroid values and response to antidepressant treatment. It was hypothesized that subjects with lower thyroid function, even within the normal range, would have a poorer response to initial treatment. METHOD: The subjects were 65 patients in the depressed phase of bipolar I disorder who were enrolled in a larger ongoing study. A panel of thyroid measures, including thyroid-stimulating hormone (TSH), thyroxine, triiodothyronine resin uptake, and free thyroxine index (FTI), were determined before initiation of algorithm-guided treatment. The effect of each thyroid measurement on time to remission was estimated by using the Cox proportional hazards model. RESULTS: Both lower values of FTI and higher values of TSH were significantly associated with longer times to remission, i.e., slower response to treatment. Outcomes were relatively poor unless patients had FTI values above the median and TSH values below the median. Patients with this optimal profile experienced remission 4 months faster than the remainder of the study group. CONCLUSIONS: This study provides further evidence that patients with bipolar disorder are particularly sensitive to variations in thyroid function within the normal range. Our results suggest that nearly three-quarters of patients with bipolar disorder have a thyroid profile that may be suboptimal for antidepressant response. It remains to be seen whether pharmacological enhancement of thyroid function will facilitate recovery from bipolar depression.

This article has been cited by other articles:

				R. Arce-Cordon, M. M. Perez-Rodriguez, E. Baca-Baldomero, M. A. Oquendo, and E. Baca-Garcia Routine Laboratory Screening Among Newly Admitted Psychiatric Patients: Is It Worthwhile? Psychiatr Serv, December 1, 2007; 58(12): 1602 - 1605. [Abstract] [Full Text] [PDF]

				R. D. Jindal and M. E. Thase Integrating Psychotherapy and Pharmacotherapy to Improve Outcomes Among Patients With Mood Disorders Focus, January 1, 2005; 3(1): 114 - 121. [Abstract] [Full Text] [PDF]

				K. R. R. Krishnan Psychiatric and Medical Comorbidities of Bipolar Disorder Psychosom Med, January 1, 2005; 67(1): 1 - 8. [Abstract] [Full Text] [PDF]

				R. D. Jindal and M. E. Thase Integration of Care: Integrating Psychotherapy and Pharmacotherapy to Improve Outcomes Among Patients With Mood Disorders Psychiatr Serv, November 1, 2003; 54(11): 1484 - 1490. [Abstract] [Full Text] [PDF]

				R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision) Focus, January 1, 2003; 1(1): 64 - 110. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us